Startup Deep Dive : Foxtale — revenue grew 2.4x in FY25 but losses grew even faster

In the financial year ended March 2025, Foxtale’s revenue from operations rose 2.4x to ₹199 crore (~$20.7 million), as reported by Entrackr from the Mumbai skincare brand’s regulatory filings. Its net loss grew even faster, up 38% to ₹73 crore in the same year — meaning the faster Foxtale sells serums and sunscreens, the more money it currently loses doing it.

That contradiction sits at the centre of one of India’s fastest-scaling direct-to-consumer skincare stories. Founded by a former investment banker who says she interviewed hundreds of Indian women before writing a single product brief, Foxtale has gone from a Chennai lab experiment to a brand fronted by Shah Rukh Khan in under five years — while still searching for the formula that turns growth into profit.

Quick facts

What they do

Foxtale sells skincare, not cosmetics — serums, sunscreens, moisturisers, cleansers and masks built around active ingredients such as vitamin C, niacinamide and peptides, priced mostly in the ₹500–1,500 mid-premium band. Its customers are young, urban Indian women, largely aged 18 to 30, who have been priced out of imported dermatologist-grade brands but have outgrown mass-market drugstore skincare. The brand sells directly through foxtale.in, through marketplaces such as Amazon, Nykaa, Flipkart and Myntra, and, increasingly, through general trade and retail counters in more than ten cities (D2CX by Inc42, January 2025).

The origin

Romita Mazumdar did not start in skincare. She studied at UCLA, then worked in investment banking at Bank of America Merrill Lynch, first covering US consumer-tech names such as Airbnb and Uber before moving to the bank’s India desk in 2018 to work on deals involving Swiggy and Zoomcar. That move taught her, in her words, that Indian and American consumer businesses were not the same animal (Founder Thesis, June 2024). Wanting to understand India’s consumer ecosystem more deeply, she joined A91 Partners, a growth-equity fund founded by former Sequoia India partners, as an analyst covering Series B and C consumer companies.

It was there, on weekends and evenings, that she began the research that became Foxtale: structured interviews with more than 900 Indian women about their skincare routines and frustrations, a number she has cited at 937 in the same interview. Three things kept coming up — that most products did not visibly solve the specific skin problem they promised, that Indian buyers wanted fast, visible results, and that most “clean beauty” brands were chasing ingredient trends rather than consistent efficacy. She set up an R&D lab in Chennai in January 2021, funding early formulation work from her own savings before the company was even incorporated, and Foxtale Consumer Private Limited was registered on 5 May 2021 (Tracxn legal-entity filing, accessed September 2026).

The struggle years

The company’s first year was also the country’s second Covid-19 wave. With manufacturing and formulation based in Chennai and Mazumdar working out of Mumbai, national lockdowns meant she could not visit the lab in person; each new formulation had to be couriered to her, adding roughly a week to every iteration cycle at a stage when speed mattered most (Founder Thesis, June 2024). Foxtale’s institutional funding did not arrive until an undisclosed seed round led by Matrix Partners India and Kae Capital in August 2021, months after incorporation, which meant the earliest R&D was self-funded (Entrackr, June 2022).

The deeper strain came later, once the brand had customers. Losses grew faster than the company could raise comfort around them: a ₹19 crore net loss in FY23 widened to ₹55 crore in FY24 and then to ₹73 crore in FY25, even as revenue climbed (SiliconIndia, January 2025; Entrackr, December 2025). Entrackr’s own reporting flagged the pace of the resulting fundraising treadmill: Foxtale closed roughly $48 million across two rounds — its Series B and Series C — within about seven months of each other between mid-2024 and early 2025, an unusually tight cycle for an Indian D2C brand still posting operating losses (Entrackr, April 2025). Running a mid-premium skincare brand at this speed, in other words, has meant raising money almost as often as it has meant launching products.

The turning point

The moment that gave Foxtale credibility with both investors and consumers was not a funding round but a single introduction. Mazumdar has described searching through LinkedIn for veteran cosmetic formulators and reaching Dr Ramesh Surin Narayanan, a formulation scientist who had worked at Hindustan Unilever — credited in her account with the Fair & Lovely (now Glow & Lovely) formulation — and later at Himalaya. Her pitch, as she recounts it: “You help me solve the formulation part, I’ll help you solve the testing.” He agreed, and Foxtale’s R&D effort went from a founder’s hypothesis to a lab with a credentialed formulator behind it (Founder Thesis, June 2024). On the numbers, that single relationship helped take the brand from a pre-revenue idea in 2021 to ₹13.8 crore in FY23 revenue and, within two more years, to ₹199 crore in FY25 — a roughly fourteen-fold increase in operating revenue in two fiscal years (Inc42, March 2024; Entrackr, December 2025).

The money behind it

Foxtale has raised money in five disclosed institutional rounds since 2021, all from the same core investor group expanding its stake over time:

• Seed round — August 2021, led by Matrix Partners India and Kae Capital, amount undisclosed (Entrackr, June 2022)
• Pre-Series A — $4 million, June 2022, led by Matrix Partners India with Kae Capital and angel investors (Entrackr, June 2022)
• Series A — ₹119 crore (~$14.4 million), March 2024, led by Singapore-based Panthera Growth Partners with Matrix Partners India and Kae Capital (Inc42, March 2024)
• Series B — $18 million, June 2024, led by Panthera Growth Partners with Matrix Partners India and Kae Capital (Inc42, June 2024)
• Series C — $30 million (~₹250 crore), announced January 2025, led by Japanese cosmetics group KOSÉ Corporation, with Z47 (formerly Matrix Partners India), Panthera Growth Partners and Kae Capital participating (Inc42, January 2025; Entrackr, April 2025)

Adding the disclosed tranches puts total funding at roughly $66 million before the undisclosed seed amount; Tracxn separately pegs cumulative funding at $56.8 million as of September 2026, a lower figure likely reflecting different FX conversions or an incomplete count of the seed round — both figures point to a company that has now raised well over $50 million. Each backer changed something specific: Matrix Partners India and Kae Capital funded the founding thesis before Foxtale had meaningful revenue; Panthera Growth Partners, a growth-stage investor, led the rounds that took the company from ₹14 crore to ₹83 crore in operating revenue; and KOSÉ Corporation, a listed Japanese beauty conglomerate, brought both capital and formulation and manufacturing relationships when it led the Series C. Post-Series C, Foxtale’s valuation stood at ₹1,530 crore (~$180 million), up from ₹795 crore (~$93.5 million) before the round — a valuation Entrackr calculated from the Series C share issue price disclosed in regulatory filings, not from a company statement (Entrackr, April 2025).

How it makes money

Foxtale earns the way most D2C skincare brands do: it manufactures through contract formulators, sells at a marked-up retail price across its own website, marketplaces and retail counters, and spends heavily on performance and celebrity marketing to acquire and retain customers. The specifics from its FY25 filings, as reported by Entrackr:

• Cost of materials: ₹74 crore in FY25, roughly doubling from ₹34 crore in FY24
• Advertising and promotion: ₹106 crore in FY25 — 38% of total expenses — more than doubling from ₹50 crore in FY24
• Employee benefit expenses: ₹31 crore in FY25, up 55% from about ₹20 crore in FY24
• Total expenses: ₹279 crore in FY25 against ₹139 crore in FY24
• Unit economics: the company spent ₹1.40 to generate every ₹1 of operating revenue in FY25, an improvement from ₹1.67 in FY24 (Entrackr, December 2025)

The part people get wrong about a brand like this is assuming the margin sits in the product. It largely does not — cost of materials is only about a third of revenue. The bigger swing factor is marketing spend: advertising alone consumed 53% of FY25 revenue, and the entire loss narrows or widens with how efficiently that spend converts to sales. Foxtale’s own reported improvement — from ₹1.67 to ₹1.40 spent per rupee earned — is the clearest sign yet that the model can, in principle, reach breakeven if advertising efficiency keeps improving rather than if the company merely sells more.

The numbers

Three consecutive years of filings show revenue scaling fast while losses widen in absolute terms, even as they shrink as a share of revenue:

(Inc42, March 2024, for FY23; SiliconIndia, January 2025, and Entrackr, December 2025, for FY24 and FY25.) Cash and bank balances have grown alongside the losses — from ₹43–44 crore at the end of FY24 to ₹166 crore at the end of FY25 — because each funding round has outpaced the cash burn, not because the business itself is throwing off cash (Entrackr, December 2025).

Where the money comes from

Foxtale’s revenue is split across three channels, based on figures tied to FY24:

• Own website (D2C): about 50% of sales, with roughly half of that from repeat customers (D2CX by Inc42, January 2025)
• Marketplaces — Amazon, Nykaa, Flipkart, Myntra: about 40% of sales (D2CX by Inc42, January 2025)
• Offline general trade and retail: about 10% of sales, present in more than ten cities with plans to expand distribution to roughly 50,000 stores across 30 cities (D2CX by Inc42, January 2025)

The surprise is less the channel mix than the direction of travel: a brand born entirely on its own website and Instagram is now pushing hardest into general trade — the unglamorous business of stocking neighbourhood chemists and beauty stores — because that is where the next layer of Indian skincare buyers, particularly outside the top metros, still shop.

The risks

• Marketing-led growth with thin cover: advertising alone was ₹106 crore against ₹199 crore of FY25 revenue — over half of sales — so any slowdown in ad efficiency or a rise in customer acquisition costs would hit the loss line directly (Entrackr, December 2025)
• A celebrity bet that needs to pay for itself: in 2025, four years after launch, Foxtale named Shah Rukh Khan as brand ambassador for its serum, moisturiser, sunscreen and mask lines under a new “Let Your Glow Through” campaign, running on 70-plus billboards across Mumbai, Bengaluru and Delhi — a marketing-heavy move that Open magazine’s analysis (August 2026) frames as risking the brand’s science-led distinctiveness in exchange for mainstream visibility, at a time when losses are still widening
• A crowded, ingredient-literate market: Foxtale competes directly with Minimalist, Deconstruct, Dr Sheth’s, Pilgrim and mCaffeine in the same ₹500–1,500 mid-premium, ingredient-first skincare segment, which industry tracking describes as the fastest-growing tier of India’s skincare market — meaning the positioning that built Foxtale’s early credibility is no longer unique to it (market intelligence coverage cited via Inventiva/Indian Retailer research, 2026)

The takeaway

Foxtale’s most transferable lesson is not about skincare at all — it is about how long a founder can keep substituting research rigour for capital before the business needs capital anyway. Mazumdar’s edge at the start was patience: hundreds of customer interviews, a 12-to-18-month product development cycle, and a formulator recruited one LinkedIn message at a time, all before the brand had meaningful revenue. That discipline built genuine credibility in a market full of trend-chasing brands. But scaling that credibility into a mainstream business has meant doing the opposite — spending on celebrity endorsement and paid marketing faster than revenue can cover it, and returning to investors every few months to fund the gap. The two instincts are not automatically compatible, and Foxtale’s next few fiscal years will show whether the same founder who built trust through patience can now build a profit line through speed.

Frequently asked questions

What does Foxtale sell?

Foxtale is a direct-to-consumer skincare brand selling serums, sunscreens, moisturisers, cleansers and masks built around specific active ingredients, priced mostly in the ₹500–1,500 range, sold through its own website, marketplaces and a growing offline retail footprint.

Who founded Foxtale and when?

Romita Mazumdar, a former investment banker and venture capital analyst, founded Foxtale; the company, Foxtale Consumer Private Limited, was incorporated in Mumbai on 5 May 2021, after R&D work began in a Chennai lab in January 2021.

How much funding has Foxtale raised, and at what valuation?

Foxtale has raised money across five disclosed rounds — a 2021 seed round, a $4 million pre-Series A in 2022, a ₹119 crore Series A in March 2024, an $18 million Series B in June 2024, and a $30 million Series C in January 2025 led by KOSÉ Corporation — taking cumulative funding to more than $50 million. Its post-Series C valuation was calculated by Entrackr at ₹1,530 crore (~$180 million) as of January 2025, based on regulatory filings.

Is Foxtale profitable?

No. Foxtale reported a net loss of ₹73 crore in FY25 on operating revenue of ₹199 crore, wider in absolute terms than its ₹55 crore loss in FY24, though the loss has been shrinking as a share of revenue as the business scales.

Who are Foxtale’s main competitors?

In India’s mid-premium, ingredient-led skincare segment, Foxtale’s closest competitors include Minimalist, Deconstruct, Dr Sheth’s, Pilgrim and mCaffeine, all positioned around active-ingredient transparency rather than legacy branding.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Entrackr (Fintrackr) — “Foxtale’s revenue nears Rs 200 Cr in FY25; losses jump 38%,” December 2025
• Entrackr (Fintrackr) — “Decoding Foxtale’s Series C funding round, latest valuation and captable,” April 2025
• Entrackr — “D2C skincare brand Foxtale raises $4 Mn in a Pre-Series A round,” June 2022
• Inc42 — “D2C Skincare Startup Foxtale Secures $30 Mn in Funding,” January 2025
• Inc42 — “Foxtale Secures INR 119 Cr To Bolster Its D2C Skincare Play,” March 2024
• Inc42 — “Foxtale Bags $18 Mn To Offer Safe Skincare Solutions To Women,” June 2024
• SiliconIndia — “Foxtale Records Rs. 83 crore Revenue in FY24 as Losses Surpass Rs. 50 crore,” January 2025
• Founder Thesis (podcast transcript) — “Romita Mazumdar: The Investor-Turned-Founder Building Foxtale,” June 2024
• D2CX by Inc42 — “Behind The 6X Revenue Rush Of Foxtale In FY24,” January 2025
• Open — “Foxed by fame: why Shah Rukh Khan is a big bet for Foxtale,” August 2026
• Tracxn — Foxtale company profile, accessed September 2026
• Tracxn — Foxtale Consumer Private Limited legal-entity filing, accessed September 2026

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.